Trial Profile
A Repeated-Dose Pharmacokinetic Evaluation of Dilaudid SR Tablets (Hydromorphone HCI) in Patients With Chronic Pain.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2017
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain
- Focus Pharmacokinetics
- Sponsors ALZA Corporation
- 28 Jul 2009 Actual patient number (22) added as reported by ClinicalTrials.gov.
- 28 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jul 2009 Actual end date (Aug 1999) added as reported by ClinicalTrials.gov.